Medexus Pharmaceuticals (TSX:MDP) Stock Can GRAFAPEX Sustain Profit Growth

Medexus Pharmaceuticals stock comes into this earnings season after a strong three month run, up about 35%, and a modest 2% gain over the past month. That sets the stage for a sentiment test rather than a rescue story. The headline today is simple: revenue reached US$28.6m with adjusted EBITDA of US$4.7m and net income of US$0.5m. The market now has to decide whether a profitable quarter with expanding GRAFAPEX contribution justifies the earlier optimism or whether investors pushed the stock too far ahead of itself.

Appreciate the profitable quarter from Medexus Pharmaceuticals but unsure whether the recent 35% run leaves enough upside? Compare it against 8 high quality undiscovered gems.

Q1 2027 Earnings Summary

• Revenue, Q1 2027 vs. Q1 2026 US$28.6m vs. US$24.6m (higher year over year)
• Net Income, Q1 2027 vs. Q1 2026 US$0.5m vs. US$0.5m (broadly flat year over year)
• Basic EPS, Q1 2027 vs. Q1 2026 Not disclosed vs. US$0.016 (comparison not available for the current quarter)
• Adjusted Gross Margin, Q1 2027 vs. Q1 2026 63.8% vs. higher prior year level (slight decline driven by a one time royalty benefit in Q1 2026)

Prefer clean visuals instead of scrolling through another wall of earnings text and tables? See Medexus Pharmaceuticals' valuation picture at a glance in an easy chart-based view with the full company report for Medexus Pharmaceuticals.

Medexus bull case hinges on GRAFAPEX execution

The optimistic view is that GRAFAPEX can reset Medexus Pharmaceuticals’ growth and margin profile and quickly scale toward the US$30–32m revenue target for FY2027. This quarter goes a long way toward proving that claim. Product revenue of US$4.9m and underlying demand of US$4.8m, up 118% year over year and 23% quarter over quarter, show real traction rather than just launch noise. Seventy five institutions have ordered and 54 have already re ordered, which supports the idea of durable adoption. Pricing is described as excellent with little discounting and NTAP support is confirmed for another year, which helps the margin narrative. At a group level, revenue of US$28.6m and adjusted EBITDA of US$4.7m, both higher than a year ago, indicate GRAFAPEX is contributing meaningfully without overwhelming cost drag.

Bear case tests concentration, cash flow and volatility

The cautious view is that Medexus is over reliant on a few products and that cash generation is inconsistent even as GRAFAPEX ramps. There is some support for that concern. Net income is flat at US$0.5m despite higher revenue and adjusted EBITDA, which shows limited drop through to the bottom line so far. Cash used by operations was US$0.7m compared with cash provided of US$3.9m a year ago, driven by working capital and payable settlements, so cash conversion looks choppy. Adjusted gross margin of 63.8% is slightly lower than the prior year, even though the comparison period had a one time royalty benefit, which challenges the idea of a sharply higher margin base already in place. Net debt has risen to US$20.9m, so any setback in GRAFAPEX uptake or tariffs affecting key products would matter more.

With operating cash turning negative and net debt at US$20.9m, investors in Medexus Pharmaceuticals cannot ignore liquidity risk. Check the full financial health analysis of Medexus Pharmaceuticals stock to verify how secure the balance sheet really is.

Stay Ahead With Simply Wall St

If the latest profitable quarter at Medexus Pharmaceuticals has your attention but the recent share price run raises questions about timing, register for free with Simply Wall St and add the stock to a Watchlist to track price against fair value and watch how the GRAFAPEX story progresses. Once you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on the most important updates to your holdings. For a broader view on sentiment and alternative angles, tap into the Community and see how other investors are thinking about the same risks and opportunities. This way you can spot potential catalysts or red flags early and give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Medexus Pharmaceuticals

Fresh ideas can move before you even spot the breakout. Use the screener while momentum is building and information is still under the radar for now, act now.

• Spot established dividend engines with staying power by reviewing 5 dividend fortresses, curated for investors who want income potential while yields are still high and attention has not fully caught up.
• Track fast moving infrastructure plays supporting AI growth by scanning 56 AI infrastructure stocks for companies building the backbone before valuations start flying and the easy entry points drop away.
• Hunt for resilient balance sheets in choppy markets through list of solid balance sheet and fundamentals stocks (12 results) so you are positioned in stronger businesses before the crowd chases safety and compresses the opportunity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com